• Vaccine Name: L. lactis-pNZ8148-BAB1-0278-Usp45 vaccine
• Target Pathogen: Brucella spp.
• Target Disease: Brucellosis
• Vaccine Ontology ID: VO_0009540
• Type: Live attenuated vaccine + Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Cattle
• Host Species as Laboratory Animal Model: Mus musculus (BALB/c mice)
• Antigen: BAB1-0278
• Preparation: The BAB1-0278 gene was cloned into the pNZ8148 vector, transformed into L. lactis, and the target protein was extracted and confirmed by SDS-PAGE and western blot. (Kazemi et al, 2023)
• Description: A vector vaccine against brucellosis was developed using recombinant Lactococcus lactis expressing the Brucella outer membrane protein BAB1-0278. Efficacy: Vaccinated mice showed significantly higher total IgG, IgG1, and IgG2a levels compared to PBS controls; increased cytokine production (IFN-γ, TNFα, IL-4, IL-10); and reduced inflammatory response, morphological impairment, alveolar edema, and lymphocyte infiltration in spleen tissue. Immune response: The vaccine induced both humoral (IgG subclasses) and cellular immunity (increased cytokines IFN-γ, TNFα, IL-4, IL-10), along with enhanced lymphocyte proliferation and modulation of innate immune markers. (Kazemi et al, 2023)

Mouse Response

• Host Strain: BALB/c
• Immune Response: The vaccine induced both humoral (IgG subclasses) and cellular immunity (increased cytokines IFN-γ, TNFα, IL-4, IL-10), along with enhanced lymphocyte proliferation and modulation of innate immune markers. (Kazemi et al, 2023)
• Challenge Protocol: Immunization of BALB/c mice followed by measurement of IgG subclasses by ELISA, cytokine production by qPCR in small intestine and spleen, lymphocyte proliferation, innate immune response markers (NLR, CRP, PLR), and histopathological examination of spleen tissue after challenge. (Kazemi et al, 2023)
• Efficacy: Vaccinated mice showed significantly higher total IgG, IgG1, and IgG2a levels compared to PBS controls; increased cytokine production (IFN-γ, TNFα, IL-4, IL-10); and reduced inflammatory response, morphological impairment, alveolar edema, and lymphocyte infiltration in spleen tissue. (Kazemi et al, 2023)
• Description: Immunization of BALB/c mice followed by measurement of IgG subclasses by ELISA, cytokine production by qPCR in small intestine and spleen, lymphocyte proliferation, innate immune response markers (NLR, CRP, PLR), and histopathological examination of spleen tissue after challenge. (Kazemi et al, 2023)